INNOVIVA, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-25
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.20%.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -6.00%, a 1100.00% decline from fiscal 2023.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.60%.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2016 was -0.29%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -0.20% 10-K · filed 2026-02-25 |
| 2024-12-31 | -6.00% 10-K · filed 2026-02-25 |
| 2023-12-31 | 0.60% 10-K · filed 2026-02-25 |
| 2016-12-31 | -0.29% 10-K · filed 2017-02-28 |
| 2015-12-31 | -0.56% 10-K · filed 2017-02-28 |
| 2014-12-31 | -4.04% 10-K · filed 2017-02-28 |
| 2013-12-31 | -2.51% 10-K · filed 2016-02-24 |
| 2012-12-31 | -2.09% 10-K · filed 2015-02-27 |
| 2011-12-31 | 0.75% 10-K · filed 2014-03-03 |
| 2010-12-31 | -0.05% 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |